Scott T Michalski
Overview
Explore the profile of Scott T Michalski including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
148
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sorscher S, Lopiccolo J, Heald B, Chen E, Bristow S, Michalski S, et al.
JCO Precis Oncol
. 2023 Nov;
7:e2300190.
PMID: 37992258
Purpose: Germline genetic testing (GGT) is now recommended for all patients diagnosed with ovarian or pancreatic cancer and for a large proportion of patients based solely on a diagnosis of...
2.
Ossa Gomez C, Achatz M, Hurtado M, Sanabria-Salas M, Sullcahuaman Y, Chavarri-Guerra Y, et al.
JCO Glob Oncol
. 2022 Jul;
8:e2200104.
PMID: 35867948
Purpose: To report on pathogenic germline variants detected among individuals undergoing genetic testing for hereditary breast and/or ovarian cancer (HBOC) from Latin America and compare them with self-reported Hispanic individuals...
3.
Heald B, Mokhtary S, Nielsen S, Rojahn S, Yang S, Michalski S, et al.
Gynecol Oncol
. 2022 Jun;
166(2):344-350.
PMID: 35691755
Objective: Hereditary uterine cancer (UC) is traditionally associated with pathogenic/likely pathogenic germline variants (PGVs) in Lynch syndrome genes or PTEN; however, growing evidence supports a role for other genes that...
4.
Espinel W, Champine M, Hampel H, Jeter J, Sweet K, Pilarski R, et al.
Cancers (Basel)
. 2022 May;
14(10).
PMID: 35626031
Consensus guidelines for hereditary breast and ovarian cancer include management recommendations for pathogenic/likely pathogenic (P/LP) variants in , , and other DNA damage repair (DDR) genes beyond or . We...
5.
Muller C, Nielsen S, Hatchell K, Yang S, Michalski S, Hamlington B, et al.
JCO Precis Oncol
. 2021 Sep;
5.
PMID: 34585040
Purpose: Strict clinical criteria used by Medicare for germline testing for Lynch syndrome (LS) could lead to missed diagnoses of hereditary cancer syndromes given variable individual and family phenotypes. The...
6.
Berry D, Wang X, Michalski S, Kang H, Yang S, Creelan B, et al.
JCO Precis Oncol
. 2021 Jun;
4.
PMID: 34164592
No abstract available.
7.
Clark D, Michalski S, Tondon R, Nehoray B, Ebrahimzadeh J, Hughes S, et al.
Genet Med
. 2020 Feb;
22(5):840-846.
PMID: 32051609
Purpose: CTNNA1 is a potential diffuse gastric cancer risk gene, however CTNNA1 testing on multigene panel testing (MGPT) remains unstudied. Methods: De-identified data from 151,425 individuals who underwent CTNNA1 testing...
8.
Yang S, Axilbund J, OLeary E, Michalski S, Evans R, Lincoln S, et al.
Ann Surg Oncol
. 2018 Jul;
25(10):2925-2931.
PMID: 29998407
Background: An estimated 5-10% of breast and ovarian cancers are due to hereditary causes such as hereditary breast and ovarian cancer (HBOC) syndrome. Medicare, the third-party payer that covers 44...
9.
Chan S, Lim W, Michalski S, Lim J, Ishak N, Met-Domestici M, et al.
NPJ Genom Med
. 2017 Dec;
1:16015.
PMID: 29263814
Li-Fraumeni syndrome (LFS) is a rare cancer predisposition syndrome usually associated with germline alterations. Its genetic basis in wild-type pedigrees is less understood. Using whole-genome sequencing, we identified a germline...
10.
OLeary E, Iacoboni D, Holle J, Michalski S, Esplin E, Yang S, et al.
Ann Surg Oncol
. 2017 Aug;
24(10):3060-3066.
PMID: 28766213
Background: Clinicians ordering multi-gene next-generation sequencing panels for hereditary breast cancer risk have a variety of test panel options. Many panels include lesser known breast cancer genes or genes associated...